Flutter rated favorably after selloff. Flutter Entertainment (FLUT) received a Buy rating from HSBC, up from Hold. Although the price target edged lower to $228 from $265, the brokerage said the stock’s retreat has improved risk-reward dynamics. HSBC cited ongoing strength in the U.S. sports-betting market and continued geographic diversification as reasons for renewed optimism.
Wolfe Research sees upside at Morgan Stanley. Investment bank Morgan Stanley (MS) was lifted to Outperform from Peer Perform by Wolfe Research, which assigned a $198 target. The note forecast faster revenue expansion, driven by anticipated share gains in investment banking and accelerating organic growth inside the firm’s wealth-management franchise. Wolfe also pointed to cost-control initiatives that could enhance operating leverage in coming quarters.
Merck receives overweight label. Wells Fargo moved pharmaceutical giant Merck (MRK) to Overweight from Equal Weight and raised its price forecast to $125 from $90. Analysts said recent business-development activity, pipeline updates and new product launches position Merck to offset the eventual loss of exclusivity for Keytruda and to sustain revenue growth into the early 2030s.
JFrog cut on valuation grounds. On the downgrades list, UBS shifted software provider JFrog (FROG) to Neutral from Buy, even as it increased its price target to $65 from $48. The report acknowledged meaningful artificial-intelligence tailwinds but estimated that the bulk of incremental revenue would not materialize for at least 12 to 18 months. UBS concluded that current valuation already reflects much of the expected upside.
Exact Sciences moved to “Hold” amid acquisition process. Jefferies lowered Exact Sciences (EXAS) to Hold from Buy and set a $105 target, up from $90. The downgrade followed Abbott’s pending acquisition of the cancer-screening company. Jefferies described the proposed takeover premium as advantageous for Exact Sciences shareholders and said a competing bid appears unlikely given historical transaction multiples.
QuantumScape tempered after sharp rally. Evercore ISI downgraded solid-state battery developer QuantumScape (QS) to In Line from Outperform and took its target to $12 from $8. With shares up roughly 200 percent year-to-date, the firm claimed valuation now captures much of the potential tied to progress on commercializing its technology.
Jazz Pharmaceuticals viewed as fairly priced. UBS reduced Jazz Pharmaceuticals (JAZZ) to Neutral from Buy, lifting the price estimate to $188 from $163. Following a favorable Phase 3 update in gastro-esophageal adenocarcinoma and a 25 percent stock advance, UBS said the company’s risk-reward profile has become more balanced.
PureCycle placed on sidelines pending execution. TD Cowen downgraded plastics-recycling firm PureCycle Technologies (PCT) to Hold from Buy and cut its price target to $9 from $16. The brokerage cited order delays and assumed further slippage in the company’s expansion timetable. Analysts indicated they will await evidence of profitability before revisiting a more constructive stance.
The rating changes arrive as investors navigate heightened volatility across sectors linked to consumer demand, health care innovation and next-generation energy solutions. Analyst opinions can influence short-term trading, yet many firms stress that their targets reflect 12-to-18-month horizons. For additional background on how analyst recommendations factor into market dynamics, readers can consult guidance from the U.S. Securities and Exchange Commission, which outlines the role of research in securities analysis.
Crédito da imagem: The Fly
